International Flavors & Fragrances Inc. (IFF) Stock Analysis
Is IFF a good investment?
International Flavors & Fragrances Inc. (IFF) has a Plutrex AI rating of 33.0/100 as of October 02, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: FCF of $536M demonstrates genuine cash generation capability despite reported earnings destruction from non-cash N&B acquisition amortization; FCF yield of ~4.9% at current market cap provides a partial valuation floor and funds dividend and debt reduction. Main concern: Catastrophic overvaluation WORSENED: PEG of 35.40x is now 719% above the industry average of 4.32x (prior: 639.7% at 30.24x) driven by P/E of 77.17x against a 5-year EPS CAGR of only 2.18%; applying industry-average P/E of 28.36x to normalized EPS of ~$1.08 yields fair value of $30-38, implying 54-63% downside from $83.12; the analyst target of $95.00 offers only 14.3% upside — grossly insufficient compensation for this risk profile.
Investment Summary
IFF at $83.12 remains a deeply overvalued specialty chemicals laggard with no fundamental case for purchase at current levels. The PEG ratio has WORSENED from 30.24x to 35.40x (+17.1%), now representing a 719% premium to the industry average of 4.32x — the single most damning valuation signal. P/E of 77.17x against a 5-year EPS growth rate of only 2.18% is economically indefensible. The stock has declined 3.2% from $85.85 to $83.12 since the prior report, which is directionally correct but insufficient — fair value under industry-average P/E of 28.36x applied to normalized EPS of ~$1.08 yields approximately $30-38, implying 54-63% downside from current prices. FCF of $536M and D/E of 0.37x (54% below the industry average of 0.81x) prevent a Strong Sell, but these positives are overwhelmed by catastrophic overvaluation, -91.6% earnings growth, ROE of only 1.83% (industry: 10.68%), and operating margin of 8.50% (industry: 18.98%). The India price-collusion investigation remains an unresolved regulatory overhang per Headline: 'India investigates fragrance giants over price collusion, document shows.' GLP-1 consumer research (Headline: 'IFF Report Finds GLP-1 Is Reshaping Food Choices...') represents long-term optionality but zero near-term earnings catalyst. New product launches (AQUASCENT, Omni-Bos) are incremental, not transformative. Analyst consensus target of $95.00 implies 14.3% upside — wholly inadequate compensation for a stock with 54-63% fundamental downside risk.
Key Strengths
- FCF of $536M demonstrates genuine cash generation capability despite reported earnings destruction from non-cash N&B acquisition amortization; FCF yield of ~4.9% at current market cap provides a partial valuation floor and funds dividend and debt reduction
- D/E of 0.37x is 54.3% below the industry average of 0.81x — IFF carries dramatically less financial leverage than peers, reducing bankruptcy risk and providing post-divestiture capital deployment optionality alongside $569M in cash
- Forward 1-year EPS growth of 16.49% exceeds the industry average of 10.78% by 53%, representing a credible near-term base-effect recovery; Food Ingredients and SCL disposal groups being reported as discontinued operations simplifies the business and may accelerate margin normalization
Key Concerns
- Catastrophic overvaluation WORSENED: PEG of 35.40x is now 719% above the industry average of 4.32x (prior: 639.7% at 30.24x) driven by P/E of 77.17x against a 5-year EPS CAGR of only 2.18%; applying industry-average P/E of 28.36x to normalized EPS of ~$1.08 yields fair value of $30-38, implying 54-63% downside from $83.12; the analyst target of $95.00 offers only 14.3% upside — grossly insufficient compensation for this risk profile
- Structural profitability and regulatory crisis UNCHANGED: ROE of 1.83% (industry: 10.68%, -82.9%); operating margin 8.50% (industry: 18.98%, -55.2%); earnings growth -91.6% vs industry +41.82%; India price-collusion investigation (Headline: 'India investigates fragrance giants over price collusion, document shows') remains an unresolved regulatory overhang threatening customer relationships, market access, and margins in a critical emerging-market growth segment
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
IFF's fundamentals are among the weakest in its specialty chemicals peer group on virtually every material metric. Profitability: Gross margin of 32.44% is marginally above the industry average of 31.51% (+2.9%), the sole profitability bright spot. Operating margin of 8.50% is 55.2% below the industry average of 18.98%, revealing extreme overhead cost burden post-N&B acquisition integration. Net margin of 2.78% is 62.1% below the industry average of 7.33%, compounded by heavy below-the-line amortization and interest charges. ROE of 1.83% is 82.9% below the industry average of 10.68% — the company earns less than one-fifth the equity return of its average peer, signaling deep capital destruction in economic terms. Valuation: P/E of 77.17x versus industry average of 28.36x is a 172% premium. PEG of 35.40x versus industry average of 4.32x is a 719% premium — the most extreme valuation-to-growth mismatch in the peer set. Growth: Revenue growth of 1.8% versus industry average of 15.79% (-88.6%). Earnings growth of -91.6% versus industry average of +41.82% — a 133-point differential. 5-year EPS CAGR of 2.18% versus industry average of 13.20% (-83.5%). Financial Health: D/E of 0.37x is 54% below industry average of 0.81x — the strongest relative advantage. FCF of $536M provides a valuation floor and operational flexibility. Cash of $569M offers near 1:1 FCF coverage. These health metrics prevent a Sell but do not justify current valuation by any disciplined framework.
News Sentiment
International Flavors & Fragrances is navigating a complex strategic moment — quietly reshaping its business while facing unresolved legal scrutiny that could complicate its recovery story. The company is actively repositioning itself around innovation and global consumer trends, but investors should look past the headlines carefully. On the innovation front, IFF recently introduced AQUASCENT™, a novel water-based fragrance technology that could differentiate its product lineup in a competitive market. The company also launched Omni-Bos™ PHY, a feed optimization solution for dairy producers — a niche but meaningful expansion of its agriculture-adjacent portfolio. Neither launch, however, represents a transformative revenue catalyst in the near term. Perhaps most intriguing is IFF's expanding GLP-1 consumer research program. A new report examining how the popular weight-loss drug class is reshaping food choices among Indian consumers signals that IFF is positioning itself at the intersection of health science and flavor innovation — a potentially lucrative long-term play as GLP-1 adoption grows globally. But the shadow over the company remains the India price-collusion investigation, reported by news outlets as covering fragrance giants including IFF. With India representing a critical emerging-market growth engine, any adverse regulatory finding could damage customer trust and market access at precisely the wrong time. IFF's Q2 earnings call emphasized continuing operations, excluding its Food Ingredients business and SCL disposal group — a streamlining move that may eventually sharpen the company's focus and improve margins. Whether this strategic cleanup translates into the earnings recovery investors are waiting for remains the central question.
Risk Assessment
PRIMARY RISK: Valuation compression — at P/E of 77.17x with 5-year EPS CAGR of 2.18%, any multiple normalization toward the industry average of 28.36x implies 54-63% downside to $30-38; this is the dominant risk and it is not hedged by FCF or low leverage. SECONDARY RISK: India price-collusion regulatory investigation (Headline: 'India investigates fragrance giants') — adverse findings could trigger fines, customer relationship damage, and market access restrictions in a critical growth market, compounding already-poor margin trajectory. TERTIARY RISK: Revenue stagnation at 1.8% growth versus industry average of 15.79% — without top-line acceleration, the projected 16.49% 1-year EPS recovery is purely a margin/base effect, and the collapse back to 2.18% 5-year CAGR confirms this is structural, not cyclical. MITIGATION: FCF of $536M and D/E of 0.37x provide balance sheet resilience and prevent near-term liquidity crisis. Divestiture of Food Ingredients and SCL disposal groups may release capital and simplify the business, potentially triggering a re-rating if margin recovery materializes. GLP-1 consumer research initiative (Headline: 'IFF Report Finds GLP-1 Is Reshaping Food Choices...') represents a genuine long-term product development opportunity in flavors/health sciences, but monetization is multi-year. POSITION SIZING: No more than 1.5% of portfolio given the asymmetric downside risk. FOR EXISTING HOLDERS: Hold; do not add above $74. FOR NEW INVESTORS: Do not initiate above $74; entry zone $68-$74 only.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is IFF a halal stock?
No, International Flavors & Fragrances Inc. (IFF) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for IFF?
International Flavors & Fragrances Inc. (IFF) has a Plutrex AI rating of 33.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is IFF a good investment?
According to Plutrex AI, IFF has a Sell rating (33.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in IFF?
US stocks like IFF can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in IFF?
Plutrex AI identifies the main risks for IFF by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.